Cerlapirdine

Cerlapirdine
Clinical data
ATC code	none;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name N,N-dimethyl-3-[(3-naphthalen-1-ylsulfonyl-2H-indazol-5-yl)oxy]propan-1-amine;
CAS Number	925448-93-7 ; 925447-04-7 (hydrochloride);
PubChem CID	16071605;
ChemSpider	17231095;
UNII	EK40PJ0V49;
KEGG	D10099 ;
ChEMBL	ChEMBL2103880;
CompTox Dashboard (EPA)	DTXSID201137232 ;
Chemical and physical data
Formula	C22H23N3O3S
Molar mass	409.50 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(C)CCCOc4ccc3[nH]nc(S(=O)(=O)c1cccc2ccccc12)c3c4;
	InChI InChI=1S/C22H23N3O3S/c1-25(2)13-6-14-28-17-11-12-20-19(15-17)22(24-23-20)29(26,27)21-10-5-8-16-7-3-4-9-18(16)21/h3-5,7-12,15H,6,13-14H2,1-2H3,(H,23,24); Key:NXQGEDVQXVTCDA-UHFFFAOYSA-N;

Cerlapirdine (USAN; SAM-531, WAY-262,531, PF-05212365) is a drug which was under development by Wyeth/Pfizer for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia.^[1] In a phase II clinical trial it demonstrated a trend toward efficacy along with a good side effect profile and no incidence of serious adverse events,^[2] but no further development has occurred since 2011.^[3]